<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34549976</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>23</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.</ArticleTitle><Pagination><StartPage>e0095621</StartPage><MedlinePgn>e0095621</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00956-21</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00956-21</ELocationID><Abstract><AbstractText>Dengue virus cocirculates globally as four serotypes (DENV1 to -4) that vary up to 40% at the amino acid level. Viral strains within a serotype further cluster into multiple genotypes. Eliciting a protective tetravalent neutralizing antibody response is a major goal of vaccine design, and efforts to characterize epitopes targeted by polyclonal mixtures of antibodies are ongoing. Previously, we identified two E protein residues (126 and 157) that defined the serotype-specific antibody response to DENV1 genotype 4 strain West Pac-74. DENV1 and DENV2 human vaccine sera neutralized DENV1 viruses incorporating these substitutions equivalently. In this study, we explored the contribution of these residues to the neutralization of DENV1 strains representing distinct genotypes. While neutralization of the genotype 1 strain TVP2130 was similarly impacted by mutation at E residues 126 and 157, mutation of these residues in the genotype 2 strain 16007 did not markedly change neutralization sensitivity, indicating the existence of additional DENV1 type-specific antibody targets. The accessibility of antibody epitopes can be strongly influenced by the conformational dynamics of virions and modified allosterically by amino acid variation. We found that changes at E domain II residue 204, shown previously to impact access to a poorly accessible E domain III epitope, impacted sensitivity of DENV1 16007 to neutralization by vaccine immune sera. Our data identify a role for minor sequence variation in changes to the antigenic structure that impacts antibody recognition by polyclonal immune sera. Understanding how the many structures sampled by flaviviruses influence antibody recognition will inform the design and evaluation of DENV immunogens. <b>IMPORTANCE</b> Dengue virus (DENV) is an important human pathogen that cocirculates globally as four serotypes. Because sequential infection by different DENV serotypes is associated with more severe disease, eliciting a protective neutralizing antibody response against all four serotypes is a major goal of vaccine efforts. Here, we report that neutralization of DENV serotype 1 by polyclonal antibody is impacted by minor sequence variation among virus strains. Our data suggest that mechanisms that control neutralization sensitivity extend beyond variation within antibody epitopes but also include the influence of single amino acids on the ensemble of structural states sampled by structurally dynamic virions. A more detailed understanding of the antibody targets of DENV-specific polyclonal sera and factors that govern their access to antibody has important implications for flavivirus antigen design and evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>VanBlargan</LastName><ForeName>Laura A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biological Sciences Graduate Program, University of Maryland, College Park, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milutinovic</LastName><ForeName>Pavle S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goo</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMaso</LastName><ForeName>Christina R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durbin</LastName><ForeName>Anna P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitehead</LastName><ForeName>Stephen S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Arbovirus Vaccine Research Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierson</LastName><ForeName>Theodore C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dowd</LastName><ForeName>Kimberly A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-3641-6852</Identifier><AffiliationInfo><Affiliation>Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI051967</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID)</Agency><Country/></Grant><Grant><GrantID>2T32AI051967-06A1</GrantID><Agency>NIH Institutional Training Grant- University of Maryland</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="Y">Dengue Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005416" MajorTopicYN="N">Flavivirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008968" MajorTopicYN="Y">Molecular Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="Y">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">humoral immunity</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">polyclonal antibody</Keyword><Keyword MajorTopicYN="N">structural dynamics</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34549976</ArticleId><ArticleId IdType="pmc">PMC8577358</ArticleId><ArticleId IdType="doi">10.1128/JVI.00956-21</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. 2020. Mapping global variation in dengue transmission intensity. Sci Transl Med 12:eaax4144. 10.1126/scitranslmed.aax4144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax4144</ArticleId><ArticleId IdType="pubmed">31996463</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. 2009. Dengue: guidelines for diagnosis, treatment, prevention and control, new edition. World Health Organization, Geneva, Switzerland.</Citation></Reference><Reference><Citation>Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E. 2017. Antibody-dependent enhancement of severe dengue disease in humans. Science 358:929&#x2013;932. 10.1126/science.aan6836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan6836</ArticleId><ArticleId IdType="pmc">PMC5858873</ArticleId><ArticleId IdType="pubmed">29097492</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Alvarez M, Halstead SB. 2013. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 158:1445&#x2013;1459. 10.1007/s00705-013-1645-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-013-1645-3</ArticleId><ArticleId IdType="pubmed">23471635</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Noriega F, Ochiai RL, L'Azou M, Delore V, Skipetrova A, Verdier F, Coudeville L, Savarino S, Jackson N. 2017. A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Rev Vaccines 16:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">28590795</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, CYD 14 Study Group . 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358&#x2013;1365. 10.1016/S0140-6736(14)61060-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61060-6</ArticleId><ArticleId IdType="pubmed">25018116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortes M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, Group C-TDVW . 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195&#x2013;1206. 10.1056/NEJMoa1506223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1506223</ArticleId><ArticleId IdType="pubmed">26214039</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, CYD15 Study Group . 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113&#x2013;123. 10.1056/NEJMoa1411037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1411037</ArticleId><ArticleId IdType="pubmed">25365753</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. 2016. Dengue vaccine: WHO position paper&#x2014;July 2016. Wkly Epidemiol Rec 91:349&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">27476189</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. 2017. Dengue vaccine: WHO position paper, July 2016 - recommendations. Vaccine 35:1200&#x2013;1201. 10.1016/j.vaccine.2016.10.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.070</ArticleId><ArticleId IdType="pubmed">28185744</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Diamond MS. 2013. Flaviviruses. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 6th ed. Wolters Kluwer Health/Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Kostyuchenko VA, Zhang Q, Tan JL, Ng TS, Lok SM. 2013. Immature and mature dengue serotype 1 virus structures provide insight into the maturation process. J Virol 87:7700&#x2013;7707. 10.1128/JVI.00197-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00197-13</ArticleId><ArticleId IdType="pmc">PMC3700294</ArticleId><ArticleId IdType="pubmed">23637416</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, Baker TS, Strauss JH, Kuhn RJ, Rossmann MG. 2003. Structures of immature flavivirus particles. EMBO J 22:2604&#x2013;2613. 10.1093/emboj/cdg270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdg270</ArticleId><ArticleId IdType="pmc">PMC156766</ArticleId><ArticleId IdType="pubmed">12773377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319:1830&#x2013;1834. 10.1126/science.1153263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153263</ArticleId><ArticleId IdType="pubmed">18369147</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319:1834&#x2013;1837. 10.1126/science.1153264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153264</ArticleId><ArticleId IdType="pubmed">18369148</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Ge P, Yu X, Brannan JM, Bi G, Zhang Q, Schein S, Zhou ZH. 2013. Cryo-EM structure of the mature dengue virus at 3.5-A resolution. Nat Struct Mol Biol 20:105&#x2013;110. 10.1038/nsmb.2463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2463</ArticleId><ArticleId IdType="pmc">PMC3593067</ArticleId><ArticleId IdType="pubmed">23241927</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717&#x2013;725. 10.1016/s0092-8674(02)00660-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(02)00660-8</ArticleId><ArticleId IdType="pmc">PMC4152842</ArticleId><ArticleId IdType="pubmed">11893341</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshuber S, Allison SL, Heinz FX, Mandl CW. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol 84:183&#x2013;191. 10.1099/vir.0.18723-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.18723-0</ArticleId><ArticleId IdType="pubmed">12533715</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Diamond MS. 2012. Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol 2:168&#x2013;175. 10.1016/j.coviro.2012.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2012.02.011</ArticleId><ArticleId IdType="pmc">PMC3715965</ArticleId><ArticleId IdType="pubmed">22445964</ArticleId></ArticleIdList></Reference><Reference><Citation>de Silva AM, Harris E. 2017. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The path to a dengue vaccine: learning from human natural dengue infection studies and vaccine trials. Cold Spring Harb Perspect Biol 10:a028811. 10.1101/cshperspect.a029371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a029371</ArticleId><ArticleId IdType="pmc">PMC5983190</ArticleId><ArticleId IdType="pubmed">28716891</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz FX, Stiasny K. 2012. Flaviviruses and their antigenic structure. J Clin Virol 55:289&#x2013;295. 10.1016/j.jcv.2012.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2012.08.024</ArticleId><ArticleId IdType="pubmed">22999801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Lok SM. 2016. The development of therapeutic antibodies against dengue virus. Antiviral Res 128:7&#x2013;19. 10.1016/j.antiviral.2016.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.01.002</ArticleId><ArticleId IdType="pubmed">26794397</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Pierson TC, Fremont DH. 2008. The structural immunology of antibody protection against West Nile virus. Immunol Rev 225:212&#x2013;225. 10.1111/j.1600-065X.2008.00676.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00676.x</ArticleId><ArticleId IdType="pmc">PMC2646609</ArticleId><ArticleId IdType="pubmed">18837784</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6:e1000823. 10.1371/journal.ppat.1000823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000823</ArticleId><ArticleId IdType="pmc">PMC2848552</ArticleId><ArticleId IdType="pubmed">20369024</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11:522&#x2013;530. 10.1038/nm1240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1240</ArticleId><ArticleId IdType="pmc">PMC1458527</ArticleId><ArticleId IdType="pubmed">15852016</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. 2012. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429:12&#x2013;20. 10.1016/j.virol.2012.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.03.003</ArticleId><ArticleId IdType="pmc">PMC3683589</ArticleId><ArticleId IdType="pubmed">22537810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103&#x2013;113. 10.1016/j.virol.2009.06.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.037</ArticleId><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey FA, Stiasny K, Vaney MC, Dellarole M, Heinz FX. 2018. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep 19:206&#x2013;224. 10.15252/embr.201745302.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201745302</ArticleId><ArticleId IdType="pmc">PMC5797954</ArticleId><ArticleId IdType="pubmed">29282215</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NTH, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170&#x2013;177. 10.1038/ni.3058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3058</ArticleId><ArticleId IdType="pmc">PMC4445969</ArticleId><ArticleId IdType="pubmed">25501631</ArticleId></ArticleIdList></Reference><Reference><Citation>Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U, Roggendorf M, Roggendorf H, Allwinn R, Heinz FX. 2013. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog 9:e1003458. 10.1371/journal.ppat.1003458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003458</ArticleId><ArticleId IdType="pmc">PMC3688551</ArticleId><ArticleId IdType="pubmed">23818856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarmer J, Zlatkovic J, Tsouchnikas G, Vratskikh O, Strau&#xdf; J, Aberle JH, Chmelik V, Kundi M, Stiasny K, Heinz FX. 2014. Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J Virol 88:13845&#x2013;13857. 10.1128/JVI.02086-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02086-14</ArticleId><ArticleId IdType="pmc">PMC4248988</ArticleId><ArticleId IdType="pubmed">25253341</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Despres P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA. 2015. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520:109&#x2013;113. 10.1038/nature14130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14130</ArticleId><ArticleId IdType="pubmed">25581790</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins MH, Tu HA, Gimblet-Ochieng C, Liou GA, Jadi RS, Metz SW, Thomas A, McElvany BD, Davidson E, Doranz BJ, Reyes Y, Bowman NM, Becker-Dreps S, Bucardo F, Lazear HM, Diehl SA, de Silva AM. 2019. Human antibody response to Zika targets type-specific quaternary structure epitopes. JCI Insight 4 10.1172/jci.insight.124588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.124588</ArticleId><ArticleId IdType="pmc">PMC6538335</ArticleId><ArticleId IdType="pubmed">30996133</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WMPB, Kraus A, Olivarez NP, Pham Q, Brien JD, Brian J, Tsai W-Y, Wang W-K, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e1188. 10.1371/journal.pntd.0001188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001188</ArticleId><ArticleId IdType="pmc">PMC3119640</ArticleId><ArticleId IdType="pubmed">21713020</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271&#x2013;283. 10.1016/j.chom.2010.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE, Jr.. 2013. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 207:1898&#x2013;1908. 10.1093/infdis/jit119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit119</ArticleId><ArticleId IdType="pmc">PMC3654755</ArticleId><ArticleId IdType="pubmed">23526830</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC. 2013. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog 9:e1003761. 10.1371/journal.ppat.1003761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003761</ArticleId><ArticleId IdType="pmc">PMC3857832</ArticleId><ArticleId IdType="pubmed">24348242</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109:7439&#x2013;7444. 10.1073/pnas.1200566109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200566109</ArticleId><ArticleId IdType="pmc">PMC3358852</ArticleId><ArticleId IdType="pubmed">22499787</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG, Durbin AP, Whitehead SS, De Silva AM, Baric RS. 2019. Beyond neutralizing antibody levels: the epitope specificity of antibodies induced by National Institutes of Health monovalent dengue virus vaccines. J Infect Dis 220:219&#x2013;227. 10.1093/infdis/jiz109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz109</ArticleId><ArticleId IdType="pmc">PMC6581895</ArticleId><ArticleId IdType="pubmed">30895307</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH. 2012. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 8:e1002930. 10.1371/journal.ppat.1002930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002930</ArticleId><ArticleId IdType="pmc">PMC3464233</ArticleId><ArticleId IdType="pubmed">23055922</ArticleId></ArticleIdList></Reference><Reference><Citation>Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS. 2010. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84:10630&#x2013;10643. 10.1128/JVI.01190-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01190-10</ArticleId><ArticleId IdType="pmc">PMC2950583</ArticleId><ArticleId IdType="pubmed">20702644</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd KA, DeMaso CR, Pierson TC. 2015. Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing. mBio 6:e01559-15. 10.1128/mBio.01559-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01559-15</ArticleId><ArticleId IdType="pmc">PMC4631804</ArticleId><ArticleId IdType="pubmed">26530385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84:9227&#x2013;9239. 10.1128/JVI.01087-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01087-10</ArticleId><ArticleId IdType="pmc">PMC2937608</ArticleId><ArticleId IdType="pubmed">20592088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS. 2013. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol 87:8826&#x2013;8842. 10.1128/JVI.01314-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01314-13</ArticleId><ArticleId IdType="pmc">PMC3754038</ArticleId><ArticleId IdType="pubmed">23785205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. 2010. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 6:e1000821. 10.1371/journal.ppat.1000821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000821</ArticleId><ArticleId IdType="pmc">PMC2841629</ArticleId><ArticleId IdType="pubmed">20333252</ArticleId></ArticleIdList></Reference><Reference><Citation>Flipse J, Smit JM. 2015. The complexity of a dengue vaccine: a review of the human antibody response. PLoS Negl Trop Dis 9:e0003749. 10.1371/journal.pntd.0003749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003749</ArticleId><ArticleId IdType="pmc">PMC4465930</ArticleId><ArticleId IdType="pubmed">26065421</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Escalante AA, Pujol FH, Ludert JE, Tovar D, Salas RA, Liprandi F. 2002. Diversity and evolution of the envelope gene of dengue virus type 1. Virology 303:110&#x2013;119. 10.1006/viro.2002.1686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2002.1686</ArticleId><ArticleId IdType="pubmed">12482662</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver SC, Vasilakis N. 2009. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect Genet Evol 9:523&#x2013;540. 10.1016/j.meegid.2009.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2009.02.003</ArticleId><ArticleId IdType="pmc">PMC3609037</ArticleId><ArticleId IdType="pubmed">19460319</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC. 2014. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J Virol 88:11726&#x2013;11737. 10.1128/JVI.01140-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01140-14</ArticleId><ArticleId IdType="pmc">PMC4178732</ArticleId><ArticleId IdType="pubmed">25078693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC. 2008. Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology 381:67&#x2013;74. 10.1016/j.virol.2008.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.08.021</ArticleId><ArticleId IdType="pmc">PMC3428711</ArticleId><ArticleId IdType="pubmed">18801552</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, McArthur J, Marron JA, Blaney JE, Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS. 2006. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2:167&#x2013;173. 10.4161/hv.2.4.2944.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.2.4.2944</ArticleId><ArticleId IdType="pubmed">17012875</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. 2013. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 207:957&#x2013;965. 10.1093/infdis/jis936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis936</ArticleId><ArticleId IdType="pmc">PMC3571448</ArticleId><ArticleId IdType="pubmed">23329850</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC. 2011. A single dose of the DENV-1 candidate vaccine rDEN1Delta30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Negl Trop Dis 5:e1267. 10.1371/journal.pntd.0001267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001267</ArticleId><ArticleId IdType="pmc">PMC3149013</ArticleId><ArticleId IdType="pubmed">21829748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatcher EL, Zhdanov SA, Bao Y, Blinkova O, Nawrocki EP, Ostapchuck Y, Schaffer AA, Brister JR. 2017. Virus variation resource&#x2014;improved response to emergent viral outbreaks. Nucleic Acids Res 45:D482&#x2013;D490. 10.1093/nar/gkw1065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1065</ArticleId><ArticleId IdType="pmc">PMC5210549</ArticleId><ArticleId IdType="pubmed">27899678</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229&#x2013;238. 10.1016/j.chom.2008.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2008.08.004</ArticleId><ArticleId IdType="pmc">PMC2678546</ArticleId><ArticleId IdType="pubmed">18779049</ArticleId></ArticleIdList></Reference><Reference><Citation>Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15:312&#x2013;317. 10.1038/nsmb.1382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.1382</ArticleId><ArticleId IdType="pubmed">18264114</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80:12149&#x2013;12159. 10.1128/JVI.01732-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01732-06</ArticleId><ArticleId IdType="pmc">PMC1676294</ArticleId><ArticleId IdType="pubmed">17035317</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiasny K, Kiermayr S, Holzmann H, Heinz FX. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80:9557&#x2013;9568. 10.1128/JVI.00080-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00080-06</ArticleId><ArticleId IdType="pmc">PMC1617264</ArticleId><ArticleId IdType="pubmed">16973559</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 4:e1000060. 10.1371/journal.ppat.1000060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000060</ArticleId><ArticleId IdType="pmc">PMC2330159</ArticleId><ArticleId IdType="pubmed">18464894</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS. 2011. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol 85:11567&#x2013;11580. 10.1128/JVI.05859-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05859-11</ArticleId><ArticleId IdType="pmc">PMC3209272</ArticleId><ArticleId IdType="pubmed">21917960</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH. 2009. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J 28:3269&#x2013;3276. 10.1038/emboj.2009.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.245</ArticleId><ArticleId IdType="pmc">PMC2771083</ArticleId><ArticleId IdType="pubmed">19713934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC. 2014. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol 88:7210&#x2013;7220. 10.1128/JVI.03690-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03690-13</ArticleId><ArticleId IdType="pmc">PMC4054442</ArticleId><ArticleId IdType="pubmed">24741083</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd KA, Pierson TC. 2018. The many faces of a dynamic virion: implications of viral breathing on flavivirus biology and immunogenicity. Annu Rev Virol 5:185&#x2013;207. 10.1146/annurev-virology-092917-043300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092917-043300</ArticleId><ArticleId IdType="pubmed">30265634</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Ng TS, Kostyuchenko VA, Lee J, Lee S, Wang J, Lok SM. 2013. Structural changes in dengue virus when exposed to a temperature of 37 degrees C. J Virol 87:7585&#x2013;7592. 10.1128/JVI.00757-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00757-13</ArticleId><ArticleId IdType="pmc">PMC3700303</ArticleId><ArticleId IdType="pubmed">23637405</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, Rossmann MG. 2013. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci USA 110:6795&#x2013;6799. 10.1073/pnas.1304300110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1304300110</ArticleId><ArticleId IdType="pmc">PMC3637732</ArticleId><ArticleId IdType="pubmed">23569243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XN, Shan C, Marzinek JK, Dong H, Ng TS, Ooi JSG, Fibriansah G, Wang J, Verma CS, Bond PJ, Shi PY, Lok SM. 2019. Molecular basis of dengue virus serotype 2 morphological switch from 29&#xb0;C to 37&#xb0;C. PLoS Pathog 15:e1007996. 10.1371/journal.ppat.1007996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007996</ArticleId><ArticleId IdType="pmc">PMC6752767</ArticleId><ArticleId IdType="pubmed">31536610</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog 7:e1002111. 10.1371/journal.ppat.1002111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002111</ArticleId><ArticleId IdType="pmc">PMC3128118</ArticleId><ArticleId IdType="pubmed">21738473</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick LC, Fonville JM, Gromowski GD, Bustos Arriaga J, Green A, James SL, Lau L, Montoya M, Wang C, VanBlargan LA, Russell CA, Thu HM, Pierson TC, Buchy P, Aaskov JG, Munoz-Jordan JL, Vasilakis N, Gibbons RV, Tesh RB, Osterhaus AD, Fouchier RA, Durbin A, Simmons CP, Holmes EC, Harris E, Whitehead SS, Smith DJ. 2015. Dengue viruses cluster antigenically but not as discrete serotypes. Science 349:1338&#x2013;1343. 10.1126/science.aac5017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac5017</ArticleId><ArticleId IdType="pmc">PMC4876809</ArticleId><ArticleId IdType="pubmed">26383952</ArticleId></ArticleIdList></Reference><Reference><Citation>Shihada S, Emmerich P, Thome-Bolduan C, Jansen S, Gunther S, Frank C, Schmidt-Chanasit J, Cadar D. 2017. Genetic diversity and new lineages of dengue virus serotypes 3 and 4 in returning travelers, Germany, 2006&#x2013;2015. Emerg Infect Dis 23:272&#x2013;275. 10.3201/eid2302.160751.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2302.160751</ArticleId><ArticleId IdType="pmc">PMC5324807</ArticleId><ArticleId IdType="pubmed">28098525</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D, Richards SL, Alto BW, Bettinardi DJ, Smartt CT. 2013. Genome sequence analysis of dengue virus 1 isolated in Key West, Florida. PLoS One 8:e74582. 10.1371/journal.pone.0074582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0074582</ArticleId><ArticleId IdType="pmc">PMC3787005</ArticleId><ArticleId IdType="pubmed">24098658</ArticleId></ArticleIdList></Reference><Reference><Citation>Goo L, VanBlargan LA, Dowd KA, Diamond MS, Pierson TC. 2017. A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. PLoS Pathog 13:e1006178. 10.1371/journal.ppat.1006178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006178</ArticleId><ArticleId IdType="pmc">PMC5312798</ArticleId><ArticleId IdType="pubmed">28207910</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K, Murphy BR, Whitehead SS. 2006. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2:255&#x2013;260. 10.4161/hv.2.6.3494.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.2.6.3494</ArticleId><ArticleId IdType="pubmed">17106267</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM. 2000. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74:3020&#x2013;3028. 10.1128/jvi.74.7.3020-3028.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.7.3020-3028.2000</ArticleId><ArticleId IdType="pmc">PMC111800</ArticleId><ArticleId IdType="pubmed">10708416</ArticleId></ArticleIdList></Reference><Reference><Citation>Puri B, Nelson W, Porter KR, Henchal EA, Hayes CG. 1998. Complete nucleotide sequence analysis of a Western Pacific dengue-1 virus strain. Virus Genes 17:85&#x2013;88. 10.1023/a:1008009202695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1008009202695</ArticleId><ArticleId IdType="pubmed">9778791</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW. 2006. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346:53&#x2013;65. 10.1016/j.virol.2005.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.10.030</ArticleId><ArticleId IdType="pubmed">16325883</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan LA, Davis KA, Dowd KA, Akey DL, Smith JL, Pierson TC. 2015. Context-dependent cleavage of the capsid protein by the West Nile virus protease modulates the efficiency of virus assembly. J Virol 89:8632&#x2013;8642. 10.1128/JVI.01253-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01253-15</ArticleId><ArticleId IdType="pmc">PMC4524226</ArticleId><ArticleId IdType="pubmed">26063422</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135&#x2013;145. 10.1016/j.chom.2007.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2656919</ArticleId><ArticleId IdType="pubmed">18005691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>